← ANALYST RATINGS · TIPRANKS

NeoGenomics (NEO): analyst forecast and price target

$16.65 −3.48% close 16.10.26 · market cap $2.2B · Healthcare · Medical - Diagnostics & Research IWM 0.08%
Price targets and ratings of

Analyst consensus

Strong Buy

5 Buy1 Hold0 Sell

Ratings of 6 analysts in the last 3 months · top analysts only

12-month forecast

$21.80+30.9% upside

Based on 6 price targets given in the last 3 months, the average target is $21.80, the highest $28.00, the lowest $19.00. The average is +30.9% from the last price of $16.65.

$10.00$20.00Jan 26AprJulOctJan 27AprJulOctHigh$28.00Average$21.80Low$19.00
Highest target $28.00 Average target $21.80 Lowest target $19.00
AnalystFirmPrice target RatingUpsideAction Date Move vs SPY
Lu Li★★★★★★★★★★#5185 · hits 80% · avg +11.8% UBS — Hold — Reiterated 07.10.26on TipRanks Oct 8 03:20 −3.0%next day +0.7% · 5 days +6.7%
Michael Ryskin★★★★★★★★★★#1994 · hits 58% · avg +5.1% Bank of America Securities $16.00 → $20.00+25.0% Hold +20.1% Reiterated 06.10.26on TipRanks Oct 7 04:55 −14.3%next day −3.0% · 5 days +1.1%
Michael Matson★★★★★★★★★★#1853 · hits 50% · avg +6.0% Needham $19.00 → $22.00+15.8% Buy +32.1% Reiterated 06.10.26on TipRanks 08:25 −14.3%next day −3.0% · 5 days +1.1%
David Westenberg★★★★★★★★★★#602 · hits 56% · avg +17.3% Piper Sandler $21.00 Buy +26.1% Reiterated 06.10.26on TipRanks 07:15 −14.3%next day −3.0% · 5 days +1.1%
Matt Larew★★★★★★★★★★#816 · hits 63% · avg +19.3% William Blair — Hold — Reiterated 06.10.26on TipRanks 07:10 −14.3%next day −3.0% · 5 days +1.1%
Bruce Jackson★★★★★★★★★★#12272 · hits 38% · avg −9.8% Benchmark Co. $16.00 → $20.00+25.0% Buy +20.1% Reiterated 06.10.26on TipRanks 06:55 −14.3%next day −3.0% · 5 days +1.1%
Mark Massaro★★★★★★★★★★#2635 · hits 40% · avg +5.7% BTIG $28.00 Buy +68.2% Upgrade 06.10.26on TipRanks 06:05 −14.3%next day −3.0% · 5 days +1.1%
David Westenberg★★★★★★★★★★#602 · hits 56% · avg +17.3% Piper Sandler $21.00 Buy +26.1% Reiterated 27.08.26on TipRanks 07:55 +6.7%next day −2.9% · 5 days −6.6%
Matt Larew★★★★★★★★★★#816 · hits 63% · avg +19.3% William Blair — Hold — Assigned 27.08.26on TipRanks 05:35 +6.7%next day −2.9% · 5 days −6.6%
William Bonello★★★★★★★★★★#152 · hits 66% · avg +35.0% Craig-Hallum $17.00 → $19.00+11.8% Buy +14.1% Reiterated 29.07.26on TipRanks 10:39 +15.5%next day +2.3% · 5 days −2.5%
Michael Matson★★★★★★★★★★#1853 · hits 50% · avg +6.0% Needham $15.00 → $19.00+26.7% Buy +14.1% Assigned 29.07.26on TipRanks 05:47 +15.5%next day +2.3% · 5 days −2.5%
Mark Massaro★★★★★★★★★★#2635 · hits 40% · avg +5.7% BTIG — Hold — Reiterated 28.07.26on TipRanks Jul 29 07:05 +1.7%next day +15.5% · 5 days +17.5%
Daniel Brennan★★★★★★★★★★#271 · hits 58% · avg +21.8% TD Cowen $19.00 Buy +14.1% Reiterated 28.07.26on TipRanks Jul 29 01:50 +1.7%next day +15.5% · 5 days +17.5%
Bruce Jackson★★★★★★★★★★#12272 · hits 38% · avg −9.8% Benchmark Co. $11.00 → $16.00+45.5% Buy −3.9% Reiterated 24.07.26on TipRanks 08:01 −2.6%next day −5.4% · 5 days +9.0%
Michael Ryskin★★★★★★★★★★#1994 · hits 58% · avg +5.1% Bank of America Securities $11.00 → $16.00+45.5% Hold −3.9% Reiterated 13.07.26on TipRanks 06:10 +0.8%next day +0.5% · 5 days +1.9%
Unknown Analyst Stephens $15.50 Buy −6.9% Reiterated 29.04.26on TipRanks 09:35 −0.6%next day +2.4% · 5 days −3.9%
Puneet Souda★★★★★★★★★★#2942 · hits 45% · avg +4.1% Leerink Partners $25.00 Buy +50.2% Upgrade 29.04.26on TipRanks 06:25 −0.6%next day +2.4% · 5 days −3.9%
Unknown Analyst Jefferies $15.00 Buy −9.9% Reiterated 18.02.26on TipRanks 14:15 −10.8%next day −2.2% · 5 days −5.3%
Unknown Analyst Guggenheim — Hold — Reiterated 17.02.26on TipRanks Feb 18 07:35 +0.4%next day −10.8% · 5 days −16.3%

Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst

Best analysts covering NeoGenomics

TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.

Most accurate

3 months David Westenberg★★★★★★★★★★Piper Sandler · #602
Hits 56%174 of 310 Average return +17.3%
1 year Daniel Brennan★★★★★★★★★★TD Cowen · #271
Hits 58%280 of 485 Average return +21.8%
2 years Daniel Brennan★★★★★★★★★★TD Cowen · #271
Hits 58%280 of 485 Average return +21.8%

Most profitable

3 months David Westenberg★★★★★★★★★★Piper Sandler · #602
Hits 56%174 of 310 Average return +17.3%
1 year David Westenberg★★★★★★★★★★Piper Sandler · #602
Hits 56%174 of 310 Average return +17.3%
2 years Daniel Brennan★★★★★★★★★★TD Cowen · #271
Hits 58%280 of 485 Average return +21.8%

How the average price target moved

The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $18.33 at a price of $18.36 (−0.1%); now: $21.50 at $16.65 (+29.1%).

$16.00$18.00$20.00$22.00Sep 15Oct 1Oct 15Top analysts$21.80Average target$21.50Price$16.65

PriceAverage targetTop analysts’ target

Recommendation trend · top analysts

05101520578Oct 25366Nov277Dec73Jan 26115Feb105Mar386Apr335May344Jun64Jul84Aug74Sep142Oct

Strong BuyBuyHoldSell

Rating05.2606.2607.2608.2609.2610.26
Strong Buy330001
Buy346874
Hold544442
Sell000000

Earnings and sales forecast

Next report: 28.10.26 (Q3 2026, date not confirmed)

Earnings per share

Next quarter’s EPS estimate — $0.06 (from $0.04 to $0.07). Last quarter: $0.05.

Sales

Next quarter’s sales estimate — $207M (from $204M to $209M). Last quarter: $202M.

Best top-analyst consensus in the sector · Healthcare

AXGNAxoGen
MDWDMediwound
OCULOcular Therapeutix
OVIDOvid Therapeutics
ZYMEZymeworks
About NeoGenomics
  • CEO: Anthony Zook
  • Employees: 2,500
  • 9490 NeoGenomics Way, Fort Myers, FL, 33912, US
  • www.neogenomics.com

NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers. NeoGenomics' advanced testing capabilities encompass cytogenetics, which examines normal and abnormal chromosomes in relation to disease; fluorescence in-situ hybridization (FISH) for detecting and pinpointing specific DNA sequences and genes on chromosomes; and flow cytometry, used to measure cell population characteristics. Additionally, the company provides immunohistochemistry and digital imaging services, enabling the localization of cellular proteins in tissue sections, visualization of scanned slides, and quantitative analysis. Molecular testing, focusing on DNA/RNA analysis and gene structure/function, is also a key offering, alongside morphologic analysis where pathologists microscopically diagnose cells. Beyond clinical diagnostics, NeoGenomics supports pharmaceutical clients' oncology programs from discovery to commercialization and acts as a reference laboratory for anatomic pathology testing. The company, founded in 2001 and headquartered in Fort Myers, Florida, also maintains a strategic alliance and laboratory services agreement with Inivata Limited.

Data from the stock’s TipRanks forecast page, read 67 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗